Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100B | P04271 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | HTR2B | P41595 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5422583 | 1.00 | S100B (0.59) | S100BALDH1A1L3MBTL1HSD17B10ALOX12 | |
| Benzaldehyde Oxime SCHEMBL220641 | 0.79 | — | — | |
| Benzaldehyde Oxime SCHEMBL309201 | 0.79 | — | — | |
| Benzaldehyde Oxime SCHEMBL266504 | 0.79 | — | — | |
| SCHEMBL19018312 | 0.78 | S100B (0.83) | S100BALDH1A1L3MBTL1HSD17B10ALOX12 | |
| SCHEMBL30271866 | 0.78 | S100B (0.83) | S100BALDH1A1L3MBTL1HSD17B10ALOX12 | |
| SCHEMBL19379597 | 0.78 | S100B (0.83) | S100BALDH1A1L3MBTL1HSD17B10ALOX12 | |
| SCHEMBL25190699 | 0.77 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1HSD17B10TDP1MAPK1 | |
| SCHEMBL26154817 | 0.77 | MAPT (0.50) | HTTKMT2AMAPTMEN1LMNA | |
| SCHEMBL25190810 | 0.77 | ALDH1A1 (0.43) | S100BALDH1A1L3MBTL1ALOX12MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084645-B2 | 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-12-27 | — | — | US | disclosed |
| US-8084645-B2 | 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-12-27 | — | — | US | disclosed |
| US-20070105859-A1 | 4-Phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (mek) inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070105859-A1 | 4-Phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (mek) inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1674452-A1 | NOVEL 4-PHENYLAMINO-BENZALDOXIME DERIVATIVE AND USE THEREOF AS MEK INHIBITOR | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105859-A1 | 4-Phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (mek) inhibitors | MAPK9, MAPK4, MAPK1 | S100B 4209/4885ALDH1A1 1196/4885L3MBTL1 2127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.